Market Outlook

The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and Gilead/Kite’s Yescarta for relapsed or refractory aggressive NHL herald a new era in cancer immunotherapy. In this series of special reports, we present a comprehensive analysis of currently available and upcoming CAR T-cell therapies. This report will examine the CAR T-cell treatment landscape: the technology behind it, the hurdles to and drivers of adoption, pricing strategies, physicians’ views, and the outlook for this paradigm-shifting treatment approach.

Questions Answered

  • How is CAR T-cell therapy being adopted into medical practice? What kind of referral patterns are in place for potentially eligible patients? What is the typical patient journey for someone receiving CAR T-cell therapy?
  • What are developers doing to ensure that the myriad manufacturing issues are optimized and scalable to meet patient demand? What kind of marketing and educational programs are available to ensure that patients, physicians, and institutions are well informed about side effects, post-treatment monitoring, etc.?
  • What additional services are available for patients—e.g., specialist nurse/technician services, patient care after receiving CAR T-cell therapy, services for caregivers?
  • What pricing strategies are being implemented to cover the high cost of this therapy? Are risk-sharing and/or cost-sharing agreements in place? Are upfront payments required? What is the additional cost of patient care at specialist centers during the CAR T-cell manufacturing process and following administration?

Product Description

Special Topics Report Series is a three-wave series based on KOL interviews conducted at 1, 6, and 12 months postcommercial launch and on secondary data collected from a variety of sources. We capture physicians’ awareness, perception, and use of the launched product and anticipated future trends.

Table of contents

  • Chimeric Antigen Receptor (CAR) T-Cell Therapy - Emerging Therapies - Chimeric Antigen (CAR) T-Cell Therapy - Special Topics - US (Wave 1)

Author(s): Anamika Ghosh, Ph.D.; Rachel Webster

Anamika Ghosh, Ph.D.,is a Senior Analyst for the oncology team at Decision Resources.

Prior to joining DRG, Anamika was a Research Lead with Evalueserve Pvt. Ltd., a business solutions provider to pharmaceutical companies. At Evalueserve, she worked on various strategic insights solutions for a variety of indications, including oncology, cardiovascular, ophthalmology etc. Anamika holds a PhD on host-pathogen interactions in the context of M. tuberculosis from the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India, where she also worked as a Research Associate working on Dengue viral infection.

Rachel Webster M.Sc., D.Phil., is a senior director in the oncology and biosimilars team at Decision Resources Group, where she manages a team of analysts in producing syndicated primary and secondary market research reports on a wide range of oncology indications. She also provides sales and client support for all oncology products.

Previously, Dr. Webster was a senior analyst in the oncology group at Decision Resources. Dr. Webster has extensive experience in market forecasting with detailed expertise in cancer immunotherapies, prostate cancer, gastric cancer, and malignant melanoma. Dr Webster is also experienced in conducting primary research with physicians and payers in a wide range of oncology indications across the major pharmaceutical markets. Prior to joining Decision Resources Group, Dr. Webster was a research scientist at Immunocore in the target validation group, where her research focused on identifying target antigens expressed in cancers and autoimmune diseases using a proprietary T-cell receptor (TCR) technology platform, molecular biology and phage display techniques. Dr. Webster obtained her D.Phil., in biochemistry, M.Sc. and M.A (Hons) in biological sciences, from the University of Oxford.

Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Geographic Focus: China - China In-Depth | China

Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Landscape & Forecast - Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Epidemiology Dashboard

DRG Epidemiology’s coverage of NHL comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report...

View Details